AR095499A1 - ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b - Google Patents
ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA bInfo
- Publication number
- AR095499A1 AR095499A1 ARP140101104A ARP140101104A AR095499A1 AR 095499 A1 AR095499 A1 AR 095499A1 AR P140101104 A ARP140101104 A AR P140101104A AR P140101104 A ARP140101104 A AR P140101104A AR 095499 A1 AR095499 A1 AR 095499A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acids
- sequence
- antibody comprises
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Reivindicación 1: Un anticuerpo monoclonal capaz de unirse al complejo antitrombina (b)-heparina (ATbH), en el que la cadena pesada de dicho anticuerpo comprende: una secuencia CDR1 de aminoácidos 31 a 35 (AYRMG) de SEC ID Nº 2, una secuencia CDR2 de aminoácidos 50 a 66 (RIYSSGGRTRYADSVKG) de SEC ID Nº 2 y una secuencia CDR3 de aminoácidos 97 a 114 (AREKASDLSGSFSEALDY) de SEC ID Nº 2; y en el que la cadena ligera de dicho anticuerpo comprende: una secuencia CDR1 de aminoácidos 24 a 34 (QGDSLRSYYAS) de SEC ID Nº 1, una secuencia CDR2 de aminoácidos 50 a 56 (GKNNRPS) de SEC ID Nº 1 y una secuencia CDR3 de aminoácidos 89 a 99 (NSRDSSGNHLV) de SEC ID Nº 1. Reivindicación 20: Una composición farmacéutica que comprende una cantidad terapéuticamente eficaz del anticuerpo monoclonal de una cualquiera de las reivindicaciones 1 - 14 y un vehículo farmacéuticamente aceptable. Reivindicación 21: Un procedimiento para tratar una deficiencia o defecto genético o adquirido en la coagulación que comprende administrar una cantidad terapéuticamente eficaz de una composición farmacéutica de una cualquiera de las reivindicaciones 1 - 14 a un paciente. Reivindicación 29: Una molécula de ácido nucleico aislada que codifica un anticuerpo que se une a ATbH e inhibe la actividad anticoagulante, en la que el anticuerpo comprende una región variable de cadena pesada que comprende una secuencia de aminoácidos seleccionada del grupo que consiste en SEC ID Nº 2, 4, 6, 8 y 10.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361784590P | 2013-03-14 | 2013-03-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR095499A1 true AR095499A1 (es) | 2015-10-21 |
Family
ID=50680168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140101104A AR095499A1 (es) | 2013-03-14 | 2014-03-14 | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b |
Country Status (18)
Country | Link |
---|---|
US (4) | US9908942B2 (es) |
EP (1) | EP2970500A1 (es) |
JP (1) | JP2016519081A (es) |
KR (1) | KR20150127202A (es) |
CN (1) | CN105229033B (es) |
AR (1) | AR095499A1 (es) |
AU (1) | AU2014236198A1 (es) |
BR (1) | BR112015021399A2 (es) |
CA (1) | CA2916421A1 (es) |
HK (1) | HK1215261A1 (es) |
MX (1) | MX2015012441A (es) |
PE (1) | PE20160533A1 (es) |
RU (1) | RU2015143696A (es) |
SG (1) | SG11201506886TA (es) |
TW (1) | TW201529602A (es) |
UY (1) | UY35457A (es) |
WO (1) | WO2014153195A1 (es) |
ZA (1) | ZA201507628B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9908942B2 (en) * | 2013-03-14 | 2018-03-06 | Bayer Healthcare, Llc | Monoclonal antibodies against antithrombin β |
EP3146759B1 (en) * | 2014-05-19 | 2021-04-07 | Nokia Solutions and Networks Oy | Re-establishment procedure in dual connectivity networks |
CR20170562A (es) | 2015-06-24 | 2018-02-01 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
EP3356406A1 (en) | 2015-10-02 | 2018-08-08 | H. Hoffnabb-La Roche Ag | Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
JP2019516347A (ja) * | 2016-03-18 | 2019-06-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5578253A (en) | 1978-12-11 | 1980-06-12 | Teikoku Hormone Mfg Co Ltd | Immune measurement of hito antithrombin 3 |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
BE896543A (fr) | 1983-04-22 | 1983-08-16 | Wallone Region | Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang |
JPH0644876B2 (ja) | 1985-12-13 | 1994-06-15 | 株式会社ヤトロン | 抗トロンビン・アンチトロンビン3複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン3複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン3複合体の精製方法 |
JPH0266458A (ja) | 1988-09-01 | 1990-03-06 | Takara Shuzo Co Ltd | ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン3複合体の測定方法 |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
AU628960B2 (en) | 1989-04-07 | 1992-09-24 | Teijin Limited | Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
JPH0694713A (ja) * | 1991-07-31 | 1994-04-08 | Masashi Funayama | アンチトロンビンiii活性の測定方法とそれを用いたアンチトロンビンiii活性の測定キット |
JPH07238099A (ja) | 1994-02-25 | 1995-09-12 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体及びこれを用いる免疫学的測定法 |
FR2718849B1 (fr) | 1994-04-14 | 1996-06-14 | Pasteur Sanofi Diagnostics | Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention. |
US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
JP3841364B2 (ja) | 1994-10-18 | 2006-11-01 | 株式会社三菱化学ヤトロン | 抗ヒトビトロネクチン・トロンビン・アンチトロンビンiii 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法 |
CN1201005C (zh) | 1996-05-22 | 2005-05-11 | 维文蒂阿生物技术股份有限公司 | 特异性检测癌细胞的抗原结合片段、编码所述片段的dna、以及它们在预防和检测癌症上的用途 |
JP2000511050A (ja) | 1996-05-31 | 2000-08-29 | メディジーン・アクチェンゲゼルシャフト | 機能性分子表面の生成、スクリーニング、および展開のための新規の合成タンパク質の構造の鋳型 |
ATE381260T1 (de) | 1999-05-13 | 2008-01-15 | Gtc Biotherapeutics Inc | Transgene hergestellte antithrombin iii und deren mutanten |
JP2001321167A (ja) | 2000-05-10 | 2001-11-20 | Cosmo Research Inst | モノクローナル抗体 |
EP2281843B1 (en) | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
JP2002316999A (ja) | 2001-04-17 | 2002-10-31 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体 |
US20090226429A1 (en) | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
WO2005016236A2 (en) | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
EP1499353A4 (en) | 2002-04-15 | 2006-04-05 | Human Genome Sciences Inc | SPECIFIC TO TL5 BINDING ANTIBODIES |
CA2487901A1 (en) | 2002-05-31 | 2003-12-11 | University Of Utah Research Foundation | Variants of antithrombin iii |
EP1382615A1 (en) | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
RU2262109C2 (ru) | 2002-12-30 | 2005-10-10 | Институт биохимической физики им. Н.М. Эмануэля Российской академии наук | Способ определения концентрации антитромбина iii в плазме крови |
CN1777621A (zh) | 2003-03-14 | 2006-05-24 | Wyeth公司 | 抗人il-21受体的抗体及其应用 |
GB2404981A (en) | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
JP4931597B2 (ja) | 2003-11-07 | 2012-05-16 | イミュネックス・コーポレーション | インターロイキン−4受容体を結合する抗体 |
US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
WO2006017538A2 (en) | 2004-08-03 | 2006-02-16 | Dyax Corp. | Hk1-binding proteins |
JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
US8551920B2 (en) | 2005-02-01 | 2013-10-08 | Morpho Sys AG | Libraries and methods for isolating antibodies |
JP2010533684A (ja) | 2007-07-20 | 2010-10-28 | ユニベルシテ パリ サッド 11 | 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用 |
EP2178914A2 (en) | 2007-08-15 | 2010-04-28 | Bayer Schering Pharma Aktiengesellschaft | Monospecific and multispecific antibodies and method of use |
PT2220221E (pt) | 2007-11-29 | 2015-04-16 | Grifols Therapeutics Inc | Plasmina modificada de forma recombinante |
ES2346618B1 (es) | 2008-08-14 | 2011-08-03 | Universidad De Murcia | Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos. |
NO330078B1 (no) | 2008-09-22 | 2011-02-14 | Optipro As | Fremgangsmåte og apparat for å overvåke slitasje i sikteduker |
US20110311550A1 (en) | 2008-10-24 | 2011-12-22 | The Scripps Research Institute | Agents for hcv treatment |
AR079944A1 (es) | 2010-01-20 | 2012-02-29 | Boehringer Ingelheim Int | Anticuerpo neutralizante de la actividad de un anticoagulante |
WO2012033987A2 (en) | 2010-09-09 | 2012-03-15 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
US20140356377A1 (en) * | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
CN103930595A (zh) | 2011-11-11 | 2014-07-16 | Sio2医药产品公司 | 用于药物包装的钝化、pH保护性或润滑性涂层、涂布方法以及设备 |
US9908942B2 (en) * | 2013-03-14 | 2018-03-06 | Bayer Healthcare, Llc | Monoclonal antibodies against antithrombin β |
JP6094713B1 (ja) | 2016-06-30 | 2017-03-15 | 富士ゼロックス株式会社 | 定着部材、定着装置、及び画像形成装置 |
-
2014
- 2014-03-14 US US14/770,222 patent/US9908942B2/en not_active Expired - Fee Related
- 2014-03-14 AU AU2014236198A patent/AU2014236198A1/en not_active Abandoned
- 2014-03-14 BR BR112015021399A patent/BR112015021399A2/pt not_active IP Right Cessation
- 2014-03-14 MX MX2015012441A patent/MX2015012441A/es unknown
- 2014-03-14 CN CN201480028085.2A patent/CN105229033B/zh not_active Expired - Fee Related
- 2014-03-14 UY UY0001035457A patent/UY35457A/es not_active Application Discontinuation
- 2014-03-14 PE PE2015001972A patent/PE20160533A1/es not_active Application Discontinuation
- 2014-03-14 CA CA2916421A patent/CA2916421A1/en not_active Abandoned
- 2014-03-14 KR KR1020157028131A patent/KR20150127202A/ko not_active Application Discontinuation
- 2014-03-14 US US14/214,382 patent/US9593166B2/en not_active Expired - Fee Related
- 2014-03-14 EP EP14722465.3A patent/EP2970500A1/en not_active Withdrawn
- 2014-03-14 JP JP2016503128A patent/JP2016519081A/ja active Pending
- 2014-03-14 US US14/214,267 patent/US20140271660A1/en not_active Abandoned
- 2014-03-14 TW TW103109449A patent/TW201529602A/zh unknown
- 2014-03-14 WO PCT/US2014/029541 patent/WO2014153195A1/en active Application Filing
- 2014-03-14 RU RU2015143696A patent/RU2015143696A/ru not_active Application Discontinuation
- 2014-03-14 SG SG11201506886TA patent/SG11201506886TA/en unknown
- 2014-03-14 AR ARP140101104A patent/AR095499A1/es unknown
-
2015
- 2015-10-13 ZA ZA2015/07628A patent/ZA201507628B/en unknown
-
2016
- 2016-03-17 HK HK16103100.3A patent/HK1215261A1/zh unknown
-
2018
- 2018-02-28 US US15/908,705 patent/US10144784B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2916421A1 (en) | 2014-09-25 |
AU2014236198A1 (en) | 2015-10-15 |
SG11201506886TA (en) | 2015-09-29 |
ZA201507628B (en) | 2017-11-29 |
US20160024222A1 (en) | 2016-01-28 |
UY35457A (es) | 2014-10-31 |
RU2015143696A (ru) | 2017-04-19 |
US9908942B2 (en) | 2018-03-06 |
JP2016519081A (ja) | 2016-06-30 |
US9593166B2 (en) | 2017-03-14 |
BR112015021399A2 (pt) | 2017-07-18 |
TW201529602A (zh) | 2015-08-01 |
MX2015012441A (es) | 2016-08-08 |
CN105229033B (zh) | 2019-04-23 |
US20140271661A1 (en) | 2014-09-18 |
CN105229033A (zh) | 2016-01-06 |
HK1215261A1 (zh) | 2016-08-19 |
EP2970500A1 (en) | 2016-01-20 |
WO2014153195A1 (en) | 2014-09-25 |
PE20160533A1 (es) | 2016-06-09 |
US20180244799A1 (en) | 2018-08-30 |
US10144784B2 (en) | 2018-12-04 |
US20140271660A1 (en) | 2014-09-18 |
KR20150127202A (ko) | 2015-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos | |
AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
UA108193C2 (uk) | Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань | |
AR102592A1 (es) | Anticuerpos biespecíficos y métodos de uso en oftalmología | |
CY1121734T1 (el) | ΜΕΤΑΛΛΑΓΜΕΝΑ ΘΡΑΥΣΜΑΤΑ OspA ΚΑΙ ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ ΣΧΕΤΙΚΕΣ ΜΕ ΑΥΤΑ | |
AR105938A1 (es) | Anticuerpo anti-epha4 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |